Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,586 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07308132RecruitingPhase 1
Study of a new drug for certain lymphomas
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
ClaytonAges 18 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06332755RecruitingPhase 1
Study of LB-LR1109 alone and with atezolizumab for cancer
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
Fairfax, VirginiaAges 18 years+ - NCT06349044Recruiting
Radiation and immunotherapy with or without probiotics for advanced digestive cancers
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
Hangzhou, ZhejiangAges 18–75 - NCT06350994Recruiting
Early Heart Check After CAR-T Cell Treatment
This study checks your heart function early after CAR-T cell cancer treatment. It uses a quick heart ultrasound to look for changes soon after the infusion.
ParisAges 18 years+ - NCT06357754Recruiting
Testing tumor samples after BMS cell therapy and a second cancer
This trial offers testing of tumor samples for people who developed a new, different cancer after receiving a Bristol-Myers Squibb gene-modified cell therapy. The goal is to understand the genetics of that new cancer and see if it relates to the prior treatment.
Portland, OregonAges Any age - NCT06364553Recruiting
Metal stent for swallowing problems from cancer
This study tests whether a metal tube (stent) placed in the esophagus can safely improve swallowing in people whose cancer blocks the food pipe and cannot be cured. It may help you eat and drink more comfortably.
Rotterdam, South HollandAges 18 years+ - NCT06373471Recruiting
Geriatric assessment for older frail adults with blood cancer
This trial tests whether a special check-up (called a geriatric assessment) can improve quality of life for older adults with blood cancer who are also frail. The goal is to help you feel better and manage treatments more effectively.
Odense CAges 70 years+ - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT06377059Recruiting
Early detection of complications during immunotherapy
This trial uses special equipment to watch for early side effects in people getting CAR T-cell therapy or bispecific antibodies for blood cancers, like lymphoma. It aims to catch problems early so they can be treated faster.
Copenhagen OAges 18 years+ - NCT06377696RecruitingPhase 2
Metformin study for brain tumor survivors after radiation
This study tests whether metformin, a common diabetes medicine, can help protect thinking and memory skills in people who have had radiation for a brain tumor. You will use a smartwatch and take online tests from home to track your progress.
Rochester, MinnesotaAges 18 years+ - NCT06378138RecruitingPhase 2/Phase 3
Testing a new drug combo for untreated CLL or SLL
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
Bengbu, AnhuiAges 18–80 - NCT06381726Recruiting
Personalized brain mapping to protect movement during glioma surgery
This study tests a personalized approach to map and protect the brain's movement pathways during surgery for slow-growing brain tumors. The goal is to remove as much tumor as possible while keeping your quality of life and movement abilities intact.
Milan, LombardyAges 18 years+ - NCT06383520RecruitingEarly Phase 1
PET imaging for GPC3 in liver cancer
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Wuhan, HubeiAges 18–65 - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06408194RecruitingPhase 1
CD22 CAR T cells after Kymriah for B-cell cancers
This trial tests a new CAR T-cell therapy that targets CD22, after you've already received or been scheduled for a standard CD19-targeting CAR T-cell therapy (Kymriah). The goal is to see if giving a second type of CAR T cells can help when the first one doesn't work or the cancer returns.
Palo Alto, CaliforniaAges 1–25 - NCT06409767Recruiting
Early warning system for blood cancer patients on chemo or transplant
This study tests whether a special early warning system can help doctors spot problems sooner in people with blood cancers who are getting strong chemo or a stem cell transplant. The goal is to improve outcomes by catching complications early.
AmiensAges 18 years+ - NCT06413212Recruiting
Personalized drug test for advanced cancer with fluid buildup
This trial uses a special test on your cancer cells to find which chemotherapy might work best for you. The aim is to treat advanced cancer that has caused fluid buildup in the chest or abdomen.
Wuhan, HubeiAges 18 years+ - NCT06416761Recruiting
Genetics and kidney disease progression study
This study looks at how genetics affect the progression of kidney diseases. Joining may help researchers understand your condition better and find better treatments.
MilanAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06434662RecruitingPhase 2
Combination therapy for relapsed or refractory AML
This trial tests a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—for people with AML that has come back or not responded to standard treatment. It aims to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,586 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.